Clearing amyloid plaques may break the chain reaction that fuels brain cell destruction in Alzheimer’s disease. One Alzheimer’s brain offered researchers something they almost never get to see: a natural side-by-side experiment. In some regions, years of anti-amyloid treatment had removed most of the sticky plaques associated with Alzheimer’s disease (AD). Those areas contained little [...]
Cancer researchers have reported a new strategy that combines bacterial tumor targeting, nutrient deprivation and immune stimulation in a single therapeutic design. The approach uses an engineered conjugate built from L-asparaginase and flagellin, linked to a system that directs the treatment toward calreticulin-bearing cancer cells. In experiments involving Salmonella-mediated tumor therapy, the conjugate enhanced antitumor activity compared with bacterial treatment alone, according to a study published in Cell Death Discovery.
The work addresses a long-standing challenge in cancer therapy: how to make powerful treatments concentrate inside tumors while limiting damage to healthy tissues. Attenuated strains of Salmonella have attracted interest because they can preferentially accumulate in the abnormal environment of solid tumors. Tumors often contain regions with poor oxygen levels, disorganized blood vessels and local immune suppression, conditions that can support bacterial growth. Once inside these sites, therapeutic Salmonella can act as a biological delivery platform and stimulate immune responses against malignant cells.
The researchers focused on calreticulin, a protein normally found inside the endoplasmic reticulum, where it helps regulate calcium storage and protein folding. Under cellular stress, including stress caused by chemotherapy, radiation or other anticancer treatments, calreticulin can move to the outer surface of a cancer cell. There, it functions as an “eat-me” signal, alerting immune cells that the damaged cell should be engulfed. Because surface-exposed calreticulin is associated with immunogenic forms of cell death, it provides a potential molecular address for directing therapeutic agents toward stressed tumor cells.
The experimental construct combines this targeting concept with L-asparaginase, an enzyme already used in clinical oncology, especially in the treatment of acute lymphoblastic leukemia. L-asparaginase breaks down circulating L-asparagine into aspartic acid and ammonia. Some cancer cells, particularly those with limited capacity to synthesize their own asparagine, depend heavily on the amino acid supplied through the bloodstream. Depleting extracellular asparagine can therefore interrupt protein production, trigger metabolic stress and promote cancer-cell death. The enzyme’s effectiveness, however, can be limited by immune reactions, pharmacological instability and toxicity, making targeted delivery an important goal.
The second component, flagellin, is the structural protein that forms the filament of bacterial flagella. It is also a potent molecular signal for the innate immune system. Immune cells recognize flagellin primarily through Toll-like receptor 5, while intracellular sensing pathways can activate inflammasome components such as NLRC4. These signals can promote the release of inflammatory mediators, stimulate antigen-presenting cells and help convert an immunologically “cold” tumor into one more visible to the immune system. By incorporating flagellin into the therapeutic design, the researchers sought to make the treatment not only directly toxic to tumor cells but also capable of amplifying antitumor immunity.
The study’s central finding was that the calreticulin-targeting L-asparaginase–flagellin conjugate strengthened the antitumor effects of Salmonella-based therapy. Rather than relying on a single mechanism, the treatment brings together several forms of pressure on the tumor. Salmonella can concentrate within the tumor microenvironment, the targeting component can help associate the conjugate with calreticulin-exposing cancer cells, L-asparaginase can deprive vulnerable cells of an essential nutrient, and flagellin can activate immune surveillance. The resulting combination is designed to produce a chain reaction in which metabolic stress and immune stimulation reinforce one another.
This type of combination may be particularly valuable because tumors frequently adapt when exposed to one therapeutic pressure. A cancer cell that survives nutrient deprivation may still be eliminated if immune recognition is intensified. Likewise, an immune response that is too weak to control a tumor may become more effective when bacterial localization and enzyme-mediated damage increase the number of abnormal antigens and danger signals released by dying cells. The researchers’ findings suggest that coordinating these mechanisms can improve the performance of bacteria-assisted cancer treatment in experimental settings.
The approach also reflects a broader shift in cancer research toward programmable biological medicines. Instead of treating bacteria only as infectious threats, scientists are redesigning them as localized delivery vehicles capable of carrying enzymes, immune activators or molecular probes. The advantage is spatial: a therapeutic payload can be produced or concentrated near the tumor rather than distributed uniformly throughout the body. The challenge is equally significant. Any clinical version would need precise control over bacterial attenuation, immune activation, enzyme exposure and potential inflammation, while also demonstrating reliable performance across genetically diverse tumors.
Calreticulin targeting may provide a useful way to address some of that complexity because the protein’s appearance on the cell surface is linked to cellular stress and treatment response. However, the extent and duration of calreticulin exposure can vary between tumor types and individual patients. Future studies will need to determine which cancers are most suitable for this strategy, how calreticulin levels predict treatment response and whether the conjugate can be combined safely with established immunotherapies such as immune-checkpoint inhibitors. Researchers will also need to assess pharmacology, manufacturing consistency and the possibility of immune reactions against the bacterial or enzymatic components.
The findings position the engineered conjugate as a promising experimental platform rather than an immediately available therapy. By merging tumor-homing bacteria with a calreticulin-directed enzyme and an innate immune stimulant, the study illustrates how cancer treatments can be designed to attack malignant cells on multiple biological fronts. If the results are confirmed in further preclinical testing and eventually in carefully controlled clinical trials, this strategy could help turn Salmonella from a passive carrier into an active, multifunctional partner in cancer immunotherapy.
Subject of Research: Calreticulin-targeted L-asparaginase–flagellin conjugate used with Salmonella-mediated cancer therapy.
A short-term decision to eat fewer or no animal products may begin reshaping the human body at the molecular level far sooner than many people expect, according to a new study published in Nature Communications. Research by A. Simistiras, O. Bocher, C. Emmanouil and colleagues examined how restricting animal-derived foods affects both gene activity and protein production in humans, revealing a complex biological response that unfolds beneath the visible changes on a plate.
The study focuses on proteogenomics, an approach that combines two powerful layers of biological information. Genomics and transcriptomics examine the instructions encoded in DNA and the messenger RNA molecules produced when genes are activated. Proteomics, by contrast, measures the proteins that cells actually manufacture. Because proteins perform most of the body’s day-to-day work—from transporting nutrients to controlling immune reactions—studying them alongside gene activity can provide a more direct picture of how physiology responds to dietary change.
Rather than treating diet as a distant influence on long-term health, the research highlights it as an immediate biological signal. When people reduce their intake of animal products, the body is exposed to a different mixture of amino acids, fats, vitamins, minerals and other bioactive compounds. The quantity and timing of these nutrients can alter metabolic pathways, cellular signaling and the activity of genes involved in maintaining tissues. The researchers’ proteogenomic analysis was designed to capture these interconnected effects during a relatively short dietary intervention.
The significance of the work lies in its ability to distinguish between what cells are instructed to do and what they ultimately do. A gene may become more active without producing a corresponding increase in its protein, while a protein may remain stable because of slower turnover or regulation after translation. By examining both molecular layers, the study offers a more refined view of diet-responsive biology than either gene-expression or protein measurements alone. This is particularly important for nutrition research, where modest changes in multiple pathways can combine to influence health.
The findings indicate that restricting animal products can produce measurable molecular shifts even over a limited period. These changes do not represent a simple biological switch from “animal-based” to “plant-based” physiology. Instead, they appear as a network of coordinated responses involving nutrient processing, energy metabolism and cellular regulation. Some proteins may respond directly to altered nutrient availability, while others may change indirectly as tissues adapt to new metabolic demands. The result is a biological signature of dietary transition rather than a single marker that explains every effect.
Such signatures could eventually help researchers understand why individuals respond differently to the same eating pattern. Two people can consume similar diets yet experience distinct changes in blood chemistry, metabolism or immune activity because of differences in genetics, gut microorganisms, age, lifestyle and baseline health. Proteogenomic profiles may help identify these sources of variation by showing which pathways are activated in each person. In the future, that information could support more individualized nutritional guidance instead of assuming that one dietary pattern produces the same outcome for everyone.
The study also underscores an important distinction between molecular response and clinical benefit. Detecting changes in proteins or gene activity does not automatically prove that a diet will prevent disease, improve performance or extend lifespan. Molecular alterations can be adaptive, neutral or potentially harmful depending on their intensity, duration and biological context. The research therefore provides evidence that the body responds rapidly to dietary restriction, while longer and larger studies will be needed to determine how these responses relate to cardiovascular health, metabolic disease, immune function and other outcomes.
The work arrives as plant-forward diets are drawing increasing interest for environmental, ethical and health reasons. Yet public discussions often reduce the science to competing claims about whether animal products are categorically beneficial or harmful. The proteogenomic perspective offers a more nuanced alternative. It suggests that dietary effects emerge through dozens, perhaps hundreds, of interacting pathways, and that the consequences of removing or reducing a food category depend on what replaces it. A diet rich in minimally processed legumes, grains, nuts, seeds, fruits and vegetables may produce a very different molecular response from one dominated by refined plant-based products.
For scientists, the study demonstrates the value of observing dietary change across multiple biological scales. For the public, its message is both striking and practical: the body does not wait years to notice what people eat. Even short-term restriction of animal products can be reflected in the molecular machinery of human cells. The findings do not settle the broader debate over the ideal diet, but they add a new layer of evidence showing that food choices are rapidly translated into biological signals—and that understanding those signals may be key to designing healthier, more personalized nutrition strategies.
Subject of Research: The proteogenomic effects of short-term restriction of animal products in humans.
Article Title: Diet-responsive proteogenomic effects following short-term restriction of animal products in humans.
Article References: Simistiras, A., Bocher, O., Emmanouil, C. et al. Diet-responsive proteogenomic effects following short-term restriction of animal products in humans. Nature Communications (2026). https://doi.org/10.1038/s41467-026-76379-6
Image Credits: AI Generated
DOI: 10.1038/s41467-026-76379-6
Keywords: proteogenomics, nutrition, animal-product restriction, plant-based diet, gene expression, protein response, human metabolism, dietary intervention, precision nutrition
Fuchs endothelial corneal dystrophy, a progressive disorder that can gradually cloud the cornea and impair vision, may be driven by a cellular process more complex than simple cell loss. A new study published in Cell Death Discovery reports that ultraviolet-A light can induce chronic hyperploidization in corneal endothelial cells, triggering changes associated with fibrosis. The findings connect long-term genome abnormalities in post-mitotic cells to the structural deterioration observed in this increasingly recognized eye disease.
The cornea depends on a thin inner layer of endothelial cells to maintain its transparency. These cells regulate the movement of fluid between the cornea and the anterior chamber of the eye, preventing the tissue from becoming waterlogged. Unlike many cell types, human corneal endothelial cells have limited ability to divide and replenish themselves. When they are damaged or lost, neighboring cells may enlarge and stretch to cover the affected area, but this compensation has limits. In Fuchs endothelial corneal dystrophy, the endothelial layer progressively becomes dysfunctional, allowing fluid accumulation and producing corneal swelling, haze and visual distortion.
The study focuses on hyperploidization, a condition in which cells acquire extra sets or copies of chromosomes. In a healthy cell cycle, DNA is replicated and then evenly distributed when a cell divides. Post-mitotic cells, however, are not expected to continue cycling through repeated rounds of DNA replication. If DNA replication occurs without successful cell division, the result can be a cell with an enlarged genome and multiple chromosome sets. This state, known as polyploidy or hyperploidization depending on its extent and context, can alter cell size, metabolism, gene activity and responses to stress.
The researchers investigated how ultraviolet-A, or UVA, light affects cells associated with Fuchs endothelial corneal dystrophy. UVA has a longer wavelength than ultraviolet-B and can penetrate biological tissues more deeply. Although the eye possesses protective mechanisms, persistent or excessive exposure to light-generated stress can damage cellular components, including DNA, proteins and mitochondria. The study indicates that UVA exposure does not merely cause an acute injury that cells either repair or fail to survive. Instead, it can establish a chronic hyperploid state in cells that no longer divide normally.
That distinction is important because a cell can remain alive while becoming increasingly dysfunctional. Hyperploid cells may continue to produce proteins, communicate with neighboring cells and modify their surrounding environment, even as their enlarged genomes disrupt normal regulation. In the corneal endothelium, such persistent abnormalities could interfere with the machinery responsible for maintaining fluid balance and tissue transparency. The research links this long-lasting cellular state to the activation of fibrotic processes, suggesting that damaged endothelial cells may help remodel the cornea rather than simply disappearing.
Fibrosis is the formation or accumulation of excessive connective-tissue components, particularly extracellular matrix proteins such as collagens. During wound healing, matrix production can provide temporary structural support. When the response persists, however, the tissue can stiffen, become disorganized and lose its normal optical properties. In the context of Fuchs endothelial corneal dystrophy, fibrosis may contribute to the loss of corneal clarity and the progression of visual impairment. The study’s central message is that chronic hyperploidization may act as an upstream signal that pushes post-mitotic cells toward this pathological remodeling.
The findings also help explain why a disease affecting a specialized, non-dividing cell population can progress over time. A conventional view of cellular damage often emphasizes apoptosis, necrosis or the gradual depletion of functional cells. The new work highlights another possibility: injured cells may survive in a permanently altered condition and actively influence disease progression. By retaining metabolic activity while carrying abnormal quantities of DNA, these cells could produce signals that encourage inflammation, matrix deposition or changes in the behavior of nearby cells.
The UVA connection raises questions about how environmental stress interacts with inherited susceptibility. Fuchs endothelial corneal dystrophy has genetic and age-related components, and the disease does not arise from a single universal cause. The study does not establish that UVA exposure alone causes the disorder, but it provides a mechanism through which light-associated stress could worsen cellular instability in vulnerable corneal tissue. This may help researchers examine whether cumulative exposure, cellular antioxidant capacity and pre-existing genetic changes combine to determine how rapidly the disease advances.
From a treatment perspective, the work points toward targets beyond replacing lost endothelial cells. Future strategies might seek to prevent abnormal DNA replication, stabilize genome integrity, suppress the fibrotic signals released by hyperploid cells or protect the corneal endothelium from chronic light-induced stress. Such approaches would require careful testing, because polyploidy can serve useful roles in some normal tissues, and broadly blocking cell-cycle or repair pathways could produce harmful effects. The challenge will be to distinguish pathological hyperploidization from adaptive genome changes that help cells survive.
The study ultimately presents Fuchs endothelial corneal dystrophy as a disease of cellular identity as well as cellular survival. UVA-induced chronic hyperploidization appears to place post-mitotic corneal endothelial cells in a persistent state of genomic imbalance, where they can contribute to fibrosis and tissue failure. By connecting light stress, abnormal DNA content and corneal scarring, the research offers a new framework for understanding why the disease can continue even after the initial injury has passed—and provides a potential roadmap for therapies designed to interrupt the process before vision is permanently compromised.
Subject of Research: Ultraviolet-A light-induced chronic hyperploidization and fibrosis in post-mitotic corneal endothelial cells affected by Fuchs endothelial corneal dystrophy
Article Title: Ultraviolet-A light-induced chronic hyperploidization causes fibrosis in post-mitotic cells affected by Fuchs endothelial corneal dystrophy
Article References: Adhikari, Y., Parekh, M., Deshpande, N. et al. Ultraviolet-A light-induced chronic hyperploidization causes fibrosis in post-mitotic cells affected by Fuchs endothelial corneal dystrophy. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03292-8
The apparent benefits of updated COVID-19 vaccines in older adults may be influenced by more than the vaccines themselves, according to a study examining the “healthy vaccinee effect,” a form of bias that can complicate observational research. Published in Nature Communications, the work by Lyth, Spreco, Hinkula and colleagues focuses on how differences between people who receive vaccination and those who do not can alter estimates of vaccine effectiveness, particularly in elderly populations whose health status can change rapidly.
Updated COVID-19 vaccines are designed to improve protection against circulating SARS-CoV-2 variants, especially protection against severe disease, hospitalization and death. Because randomized clinical trials are not usually repeated for every reformulated vaccine and every emerging variant, researchers frequently rely on real-world health data. These studies compare outcomes among vaccinated and unvaccinated people, but the two groups may differ in important ways before vaccination occurs. Such differences can produce an apparent vaccine benefit—or obscure a real one—even when the analysis carefully accounts for age and medical conditions.
The healthy vaccinee effect arises when people who are vaccinated are temporarily healthier, more active or better connected to healthcare services than those who remain unvaccinated. Individuals may postpone vaccination during an acute illness, after hospitalization or when they are approaching the end of life. At the same time, people who attend vaccination appointments may be more likely to receive preventive care, follow medical advice and seek treatment early. These characteristics are not necessarily caused by vaccination, but they can lower the vaccinated group’s risk of death or hospitalization during the period used for analysis.
This issue is particularly important in older populations. Elderly people often have multiple chronic conditions, fluctuating functional status and frequent contact with hospitals or long-term care facilities. A person may be eligible for a vaccine campaign but unable to receive the dose because of an acute health problem. If that person later dies or is hospitalized, conventional analyses may attribute the worse outcome to the absence of vaccination, even though the underlying illness was already present. Conversely, if researchers compare groups immediately after vaccination without accounting for this selection process, the vaccine may appear more protective than it truly is.
The study evaluates how this bias affects assessments of updated COVID-19 vaccines in elderly populations. Its central scientific contribution is to treat vaccination not simply as an exposure, but as an event embedded in a changing health trajectory. The health of older adults is not static: frailty, infection, recent hospitalization and access to care can all influence whether and when vaccination occurs. By examining these time-dependent factors, the researchers draw attention to the difference between a vaccine’s biological effect and the characteristics of the people who are able to receive it at a particular moment.
In epidemiological terms, the healthy vaccinee effect is a form of confounding and selection bias. Confounding occurs when another factor is associated with both vaccination and the outcome being measured. Selection bias occurs when inclusion in the vaccinated or comparison group depends on health-related circumstances. Timing can intensify both problems. If follow-up begins on the day of vaccination for one group but at an arbitrary date for another, the groups may not have equivalent baseline risks. Researchers therefore need to define an appropriate index date, align observation periods and account for recent illness, healthcare use and changes in eligibility.
The challenge is not merely statistical. A vaccine can provide strong protection against severe COVID-19 while producing a smaller or more variable effect against infection, depending on the variant, time since vaccination, prior immunity and the outcome being studied. If an observational analysis reports a lower mortality rate among vaccinated people, that result may reflect a combination of direct vaccine protection and the healthier profile of vaccine recipients. Separating these components requires careful design, including adjustment for measured risk factors and, where possible, comparison strategies that mimic a randomized trial.
The findings have practical implications for interpreting public-health evidence. Estimates of updated vaccine effectiveness should not be read in isolation from the population being studied, the timing of vaccination and the definition of the unvaccinated comparison group. Researchers may need to conduct sensitivity analyses, use negative-control outcomes, examine short intervals after vaccination and account for healthcare-seeking behavior. Analyses that compare people with similar recent health histories, or that use methods designed for time-varying confounding, can help determine whether an observed association is likely to represent a genuine vaccine effect.
The study does not undermine the value of COVID-19 vaccination for older adults; rather, it highlights the methodological care required to measure that value accurately. For clinicians, policymakers and the public, the message is that real-world vaccine evidence is strongest when biological protection is evaluated alongside the circumstances that determine who gets vaccinated and when. As SARS-CoV-2 continues to evolve and vaccine formulations are periodically updated, understanding the healthy vaccinee effect will remain essential for distinguishing the protection delivered by immunization from the protection that appears because healthier people are more likely to receive it.
Subject of Research: Healthy vaccinee effect and the evaluation of updated COVID-19 vaccines in elderly populations.
Article Title: Healthy vaccinee effect in the evaluation of updated COVID-19 vaccines in elderly populations.
Article References:
Lyth, J., Spreco, A., Hinkula, J. et al. Healthy vaccinee effect in the evaluation of updated COVID-19 vaccines in elderly populations. Nat Commun17, 8014 (2026). https://doi.org/10.1038/s41467-026-76312-x
Ebola vaccine research has taken a step toward broader protection against one of the most persistent challenges in filovirus medicine: the existence of multiple Ebola virus species that can cause severe human disease. In a study published in Nature Communications, Weidle, Brunette, Wrenn and colleagues report that a pan-Ebolavirus nanoparticle vaccine protected rodents from lethal infection with both Zaire ebolavirus and Sudan ebolavirus. The finding is significant because vaccines designed around a single viral species may not provide reliable protection against genetically distinct Ebola viruses, particularly those responsible for separate outbreaks in different regions of Africa.
Ebola viruses belong to the filovirus family, a group of filament-shaped, enveloped viruses capable of causing hemorrhagic fever. Zaire ebolavirus is the species most closely associated with the large West African epidemic of 2014–2016 and remains the primary target of licensed Ebola vaccines. Sudan ebolavirus, however, is sufficiently different at the molecular level to present a separate immunological challenge. Outbreaks caused by Sudan virus have repeatedly demonstrated the need for countermeasures that are not limited to one viral lineage. A vaccine capable of recognizing shared features across several Ebola viruses could therefore simplify outbreak preparedness and improve the speed of emergency responses.
The strategy described in the study is based on nanoparticle vaccine technology. Nanoparticles can be engineered to present viral antigens in a highly organized, repetitive arrangement that resembles the dense surface of an actual virus. This geometry can improve the activation of B cells, the immune cells responsible for producing antibodies, by efficiently cross-linking B-cell receptors. Nanoparticles may also enhance the delivery of antigens to lymphoid tissues, where immune responses are initiated and refined. Rather than presenting a soluble protein in a relatively dispersed form, the platform is designed to display Ebola-related molecular targets in a configuration that can stimulate a stronger and more coordinated response.
A central challenge in creating a pan-Ebolavirus vaccine is selecting antigens that are both accessible to the immune system and sufficiently conserved among viral species. Ebola viruses share a broad structural organization, but their surface glycoproteins contain regions that vary in sequence and shape. The glycoprotein is especially important because it enables the virus to attach to host cells and enter them. Antibodies that bind to vulnerable regions of this protein can block infection, interfere with membrane fusion or mark viral particles for destruction by immune cells. A broadly protective vaccine must therefore encourage immunity against sites that remain functionally important even as the virus evolves.
In the rodent experiments, the vaccine was evaluated against lethal challenge with viruses representing the Zaire and Sudan species. Such challenge studies are designed to test whether vaccination-induced immunity can prevent severe disease after exposure to a high-risk pathogen. Protection in this setting reflects the combined activity of several immune mechanisms, including neutralizing antibodies, antibody-dependent cellular functions and virus-specific T-cell responses. Antibodies can prevent viral entry into cells, while T cells and other immune components help eliminate infected cells and limit the spread of infection. The reported protection across both virus species indicates that the nanoparticle formulation generated immune recognition broad enough to cross an important species barrier.
The result does not mean that the viruses are identical, nor does it establish that the vaccine will perform in humans in the same way. Rodent immune systems, dosing schedules and routes of exposure can differ substantially from human conditions. Animal challenge models are nevertheless a crucial stage in vaccine development because they reveal whether an immune response is capable of controlling infection under stringent circumstances. They also allow researchers to examine how quickly protection develops, how long it persists and whether vaccination reduces viral replication and tissue damage. Further studies will be needed to determine which immune markers best predict protection and whether the platform can be adapted for use against additional Ebola species.
The broad scope of the vaccine could have practical implications for epidemic preparedness. Existing Ebola vaccination strategies have demonstrated that immunization can protect against severe disease, but the need to match a vaccine to a particular viral species can complicate decisions during an outbreak. When the causative virus is initially unknown, health authorities may face uncertainty over which product to deploy. A pan-Ebolavirus formulation could potentially reduce that uncertainty by providing coverage against more than one major pathogen. It could also be useful for laboratory personnel, health-care workers and communities living in regions where different Ebola species may emerge over time.
Nanoparticle approaches may offer additional advantages beyond breadth. Their modular design can allow scientists to alter the antigen displayed on the particle without rebuilding the entire vaccine concept from the beginning. This flexibility is relevant to viral pathogens, which can change through mutation and may contain several related species with distinct antigenic profiles. At the same time, the platform must meet demanding standards for manufacturing consistency, stability, storage and safety. A formulation that performs well in laboratory animals must eventually demonstrate reproducible production, acceptable tolerability and durable protection in progressively more advanced models before clinical testing can be considered.
The study’s findings place nanoparticle engineering among the most promising strategies for developing next-generation filovirus vaccines. By combining multivalent antigen presentation with targets shared across Zaire and Sudan viruses, the researchers have demonstrated a route toward broader Ebola protection in rodents. The work does not eliminate the need for species-specific vaccines or replace surveillance, rapid diagnostics and infection-control measures. It does, however, provide experimental evidence that a single vaccine design can generate protective immunity against two medically important Ebola viruses. As outbreaks continue to expose gaps in preparedness, such cross-species technologies could become an important part of the scientific effort to prevent Ebola from turning a local emergence into a global health crisis.
Subject of Research: Pan-Ebolavirus nanoparticle vaccine protection against lethal Zaire and Sudan virus infection in rodents
Article Title: Pan-Ebolavirus nanoparticle vaccine provides protection in rodents from lethal infection by Zaire and Sudan viruses
Article References: Weidle, C., Brunette, N., Wrenn, S.P. et al. Pan-Ebolavirus nanoparticle vaccine provides protection in rodents from lethal infection by Zaire and Sudan viruses. Nature Communications (2026). https://doi.org/10.1038/s41467-026-76114-1
Talk about homework: a large class of undergraduates at an unnamed university in Utah became the unfortunate subject of a severe public health response after an extraordinary bungle in a science lab.
In September of last year, the group of lab students were tasked with identifying a bacterium known as P. shigelloides, a relatively harmless pathogen known to cause diarrhea when ingested. But as lab results came in, students were alarmed to find the specimens handed out in class were actually the bacteria Neisseria meningitidis, a potentially deadly pathogen that causes meningitis.
Unlike P. shigelloides, the bacterium N. meningitidis calls for high-security practices, like double gloves, disposable clothes, and fit-tested N95 masks, as the bare minimum. (In one unfortunate case from 2012, a 25-year old microbiologist whose lab was ill equipped to handle N. meningitidis died mere hours after exposure to the aerosolized microbe.)
According to People, Utah public health authorities soon raided the Utah stockroom, finding samples labeled “N. meningitidis.” That discovery prompted a recommendation that all 33 of the exposed students begin a cautionary antibiotic regimen, especially given that the lab participants were only wearing gloves and lab coats at the time of exposure.
On top of the antibiotics dose, at least two people sought medical attention due to possible exposure symptoms, which included a painful and invasive spinal tap.
It was only after the frenzy that further professional lab tests identified the offending pathogen as Neisseria sicca, a bacterium “commonly found in the upper respiratory tract” that is “nonpathogenic in immunocompetent persons,” according to a recently-filed Center for Disease Control study of the Utah lab incident.
Student misidentification notwithstanding, the event underscores the importance of accurately labeling microbial cultures — lest aspiring biologists become victims of their own studies.
As of last week, the US had recorded 2,465 confirmed infections so far this year, already more than the 2,289 total cases in 2025. The last two years saw more total infections than the rest of the 21st century combined, as The Guardian reports, with 2026’s tally beating a 35-year record.
Now, in the midst of all that crisis crisis, a character has stumbled into the narrative who perfectly illustrates how it’s gotten so bad. As the LA Times reports, a measles-infected individual spent a whopping 11 hours at the Universal Studios Hollywood theme park last month, potentially exposing countless other visitors.
The Los Angeles County Public Health Department was forced to issue a stark warning: anybody who visited the amusement park on July 26 during teh hours between 10am and 9pm may have been exposed and should monitor for symptoms including fever, cough, or rash — and stay vigilant until August 16.
The virus is contagious up to four days before the characteristic rash appears on the skin, and up to four days after that.
Measles can easily spread through the air through just via talking or breathing, and can persist on surfaces for hours at a time.
The vaccine against it, available as part of the measles, mumps, and rubella combination (MMR) shot, is extremely worthwhile. Two doses are 97 percent effective in preventing a measles infection.
The department also urged “everyone to confirm their immunity and get the vaccine if needed, especially before traveling and attending crowded events.”
California has been hit particularly hard, recording at least three localized measles outbreaks this year so far. However, according to the state’s health department, all three outbreaks have ended.
According to the Centers for Disease Control and Prevention, there have been 38 new outbreaks in 2026 across the country so far this year, with several thousand cases spanning 47 states.
The danger to one’s health is substantial — especially to the unvaccinated. According to the CDC, roughly one in five unvaccinated people in the US who get measles are hospitalized. One out of 20 children with measles develop pneumonia. and one to three of every 1,000 children who become infected die from respiratory and neurologic complications.
In case you weren’t already feeling paranoid about how AI is shaping our future, scientists for the first time have used an AI model to create new and viable viruses that have never been seen in nature.
Before you panic, the work, detailed in a study published in the journal Science, involved creating viruses that only target bacteria and are harmless to humans. Bacteriophages, as they’re called, are an important medical intervention for targeting drug-resistant pathogens.
“This is an important milestone,” Patrick Cai, a synthetic biologist at the University of Manchester who was not involved in the study, told The New York Times.
Still, it’s an alarming testament to AI’s power and trajectory. The researchers at Stanford University and the Arc Institute trained an AI model to recognize patterns of genetic structure in nature to create new DNA molecules. These molecules were inserted into bacteria that, over time, turned into wholly new viruses, at the expense of killing their hosts.
In their research, which first gained attention last year but has now been peer-reviewed, the scientists used an AI model called Evo. Unlike a general purpose large language model, Evo is trained on billions of lines of genetic sequences, and for this work in particular, millions of bacteriophage genomes. But it still functions like an LLM, predicting what DNA building blocks — nucleotides — should follow each other like a chatbot predicts what words to spit out to finish a sentence.
The researchers chose to focus on a E. coli-killing virus called Phi X-174, a variant that’s so well studied that it serves as the equivalent of a lab rat in virology. Viruses in general are simple compared to complex cellular life, making them an ideal platform to test AI’s capabilities.
They used Evo to create new viruses based on Phi X-174, and it generated 700,000 candidates. They then narrowed it down to just 300 that they would recreate in the lab. Of those 300, 16 proved to be viable, infecting and killing their bacterial hosts.
There’s clear medical merit to using AI to create bacteria-slaying viruses, but there’s already fears that the technology could be abused to crank out pathogens that are deadly to humans.
“Although this is promising for life sciences applications, it also raises urgent biosafety and biosecurity questions. The ability to compose viral genomes using generative AI now exists; the governance to safely steer it does not,” warned Tom Inglesby and Moritz Hanke at the Center for Health Security at Johns Hopkins University in Baltimore in a perspective article.
Tom Ellis, a professor of synthetic genome engineering at Imperial College London who was not involved in the research, acknowledged this threat, but told The Guardian that it would be much harder to create more complex genomes and that controlling access to genetic data could stymy the threat.
And if someone were to deliberately engineer deadly viruses, he added, doing it by hand would probably be more practical.
“But honestly, the threat from full AI design and writing of a genome of a virus or bacteria is very overblown when we consider that just taking existing pathogens and making gain-of-function changes to their genomes is so much easier and much more likely to be a real pathogenic threat,” he said.
A Massachusetts man is feeling some buyer’s remorse after securing a $5.5 million mortgage on a mansion poised to fall into the Cape Cod Bay.
The man, John Bonomi Jr, first made headlines five years ago when he purchased the sprawling 5,817-square-foot estate against warnings from area conservationists, who advised that the beach was eroding at a rate of six feet per year as rising sea levels take their toll.
Bonomi’s house, meanwhile, sat just 12 to 14 feet away from the rapidly-disappearing escarpment — and that was 2021.
Fast forward half a decade, and the situation — not to mention the mansion’s foundation — has only deteriorated as the continual lashing of ocean waves takes its toll. According to the Boston Globe, Bonomi is now trying to recoup his costs by filing suit against JP Morgan Chase, the bank that originally serviced his ill-fated mortgage.
As for his legal strategy, the property owner is essentially pleading insanity, saying that he was “acting under an uncontrollable manic psychosis at the time” he agreed to the terms of the mortgage. It’s a fascinating argument, especially because Bonomi has been diagnosed with bipolar disorder.
“No rational person… would have considered purchasing the Property, and certainly not at the full asking price,” the suit argues. “It is a recognized diagnostic fact that a symptom of bipolar disorder is irrational risk-taking and impulsive behavior, including reckless spending.”
While Bonomi may have a point — it’s astonishing that JP Morgan Chase gave him the green light, mental health episode or not — it remains to be seen whether the courts agree.
According to the Globe, the bank originally lobbied to get the case dismissed. It answered Bonomi’s filings in May, however, saying that, “to the extent a response is required, Chase denies the allegations contained therein and leaves Plaintiff to his proofs.”
Compared with standard flu shots, Moderna’s mFlusiva generates stronger, longer-lasting immunity and is more effective at preventing infection, data show.
On July 27, a billboard went up in San Francisco advertising an AI service called ChatTJB. But the “AI” powering the service, as noted in a small disclaimer on the billboard, isn’t artificial intelligence. It’s a self-avowed “average individual” named Tucker Bryant, who manually answers user queries by way of a chatbot-like interface.
An “About” page for the service defines the process as “artisanal intelligence, handcrafted by a single human being.” Or, in other words: just talking to a guy.
Bryant, a Stanford graduate and former Google employee who now works as an artist and speaker, is clear that the project isn’t designed to be anti-AI. But in an interview with Futurism, he explained that he was inspired to create ChatTJB after his romantic partner introduced him to the phrase “cognitive surrender” — a term introduced in a University of Pennsylvania study which found that AI users are overwhelmingly likely to blindly trust the advice of chatbots, even when AI-generated responses are incorrect. It resonated: Bryant felt he’d personally experienced the phenomenon during his own interactions with chatbots, so he cooked up ChatTJB as a satirical way to infuse inconvenience and unpredictability back into a chatbot-like experience.
It’s “this idea that we often, or increasingly, trust LLM outputs so easily that we stop bringing our own creativity or critical thinking into the responses we receive, and over time that weakens our ability to be fully-functioning, sovereign human beings in the world,” Bryant mused. “I thought it would be fun or interesting to create an experience that looks like the LLMs we trust a lot — that I, at least, have fallen prey to the trap of over-trusting at times — but where the experience, rather than being this super futuristic thing I think we all felt the first time we saw those cool tokens streaming on ChatGPT, would be just a really average or bad experience.”
Indeed, chatbots like OpenAI’s ChatGPT and Anthropic’s Claude are simultaneously authoritative-sounding and eager-to-please, a combination that can lead to terrible-yet-seductive advice that many users accept with little to no critical pushback. In contrast, ChatTJB’s responses are unwieldy and unpredictable. Bryant’s responses might be good; they may also be terrible, or equivocal, or otherwise bizarre and helpful. (In a social media video, Bryant says that he wants ChatTJB users “to have such an inconvenient experience with something that aesthetically looks like artificial intelligence that the next time an LLM gives you what sounds like a reasonable answer, you remember the time ChatTJB responded to your tax question with a haiku about crows.”)
Like a chatbot, he can also generate images upon request— in the form of graphics that he hastily sketches, of course.
At first, Bryant said, ChatTJB attracted a “slow trickle” of incoming queries. Which wasn’t all that surprising, given that the billboard itself isn’t exactly in a prime spot.
“It’s not a very good location — it’s obscured by trees, there’s basically no oncoming traffic that can see it, and the only way you’d get a clear look at the full billboard is if you’re parking a car in the lot right underneath it,” Bryant said. “But I was fine with that, and I also didn’t want to pay much more.” The billboard’s cost, he conceded, was “less than most used cars under 150,000 miles, but still a very irresponsible amount… $6,000 for the month, not including fees.”
But when a picture of the billboard started to make the rounds online, Bryant quickly found himself drowning in requests.
“The first couple of days I would get maybe several dozen over the course of the day. There’d be a couple hours of silence, then I’d get one inquiry, respond to that, then get a couple of other prompts from different users,” he recounted. “A few days later it started taking off into the hundreds to thousands range.” By the time Bryant made an Instagram video promoting ChatTJB, he says he was receiving about a thousand prompts a day.
“I was answering all of those,” he added. “After that is when it blew up beyond my control.”
Though many of ChatTJB’s patrons have been trolls — which Bryant says is “reasonable,” given that ChatTJB “is in some ways a troll” itself — many of the inquiries have been surprisingly tender, and at times even moving.
“Some people are just looking to chat, asking about what to make for dinner, etc. And some people are coming with their personal life stuff, and it’s been really sweet to engage with them,” said Bryant. “The one I keep coming back to — this is when I realized this isn’t just a joke to some people — was somebody a couple of days in said, ‘I’m on the first night of my honeymoon and I don’t feel relaxed, is that okay?'”
“I switched out of super-casual-mode into supportive-friend-model,” the artist continued, adding that he “acknowledged their wedding had just happened, they’d probably been anticipating it with a lot of excitement but also a lot of stress, that it was a peak moment, and now the celebration is still happening but that peak moment has passed and they’re starting what might be the rest of their life — I imagined that might feel like a strange dissonance, so I could imagine their nervous system not being settled yet, and I wondered if they were going to talk to their spouse about it.”
Often, Bryant said, users of ChatTJB have sent him reminders to take breaks and drink water as he’s worked to respond to the thousands of inputs waiting for him in ChatTJB. The reminders have been welcome.
“There were a number of days I wasn’t taking the best care of myself,” Bryant admitted. “That was also very humanizing, getting responses from people on that basis.”
It’s not just users who have been reaching out to ChatTJB. According to Bryant, he’s received over a thousand messages from aspirational “average individuals” who want to help moderate the platform and respond to inbound user inquiries. Bryant is now — carefully, he says — testing the idea of turning ChatTJB into a community project. Which, for ChatTJB users, means they’ll have to wait a while for answers.
“I’m going to move slowly,” Bryant told us. “This was just intended to be an art project. I think it’s beautiful that people want to do something less ridiculous with it than what I had planned. I also don’t want people to get hurt, so I’d rather people wait a long time for their prompts than open the floodgates to anyone and everyone. So, a long preamble to saying: I’m starting to let some approved volunteers try answering questions while testing out some moderation tools.
“We’re testing this out — so far it seems to be going fine, and it’s been tender seeing folks helping the stranger on the other end,” Bryant added. “But if it doesn’t work out, I’ll either revert or we’ll take a break from ChatTJB overall, because short term, I want to help people do what they want with it, but I don’t want anyone at risk of danger.”
Asked why he would pay thousands of dollars for a billboard — after all, he could’ve just made a website and posted about it on social media — Bryant pointed to the ubiquity of often-confusing AI billboards blanketing his city and the “cultural omniscience” of AI.
“Here in San Francisco, a lot of us have had this experience of AI billboards everywhere,” said Bryant. “There’s this cognitive dissonance I felt… in a lot of ways there are meaningful and positive changes these technologies are bringing. But at the same time, they’re associated with such anxiety about the future, and the world, and the economy, and the environment. It can feel really strange walking around and seeing all these billboards with those two sides of the conversation happening at once. So it felt like a natural extension to prod at what I’ve been referring to as the cultural omniscience that AI has — why not satirize the billboards too, because they’re part of this ecosystem.”
“That’s the highbrow answer,” Bryant added. “But the lowbrow answer is just as authentic, which is that I also thought it would be funny. I tend to overcommit to bits.”
For those who want to help Bryant pay off his billboard, there is a ChatJTB “Pro” tier. Be warned, though, that you won’t get your answers any faster if you pay up.
In case you need any more evidence that the Trump administration is run and advised by cranks, here’s the cabinet’s meat-mainlining doctor’s unvarnished thoughts on the incredible skill he displays while defecating, which he says is down to his diet.
The doctor, Sean O’Mara, is reportedly the reason why the likes of JD Vance, Robert F Kennedy Jr, and Sean Duffy have all adopted a diet based almost entirely on eating steak and fermented foods like kimchi.
When New York Times reporter Willy Staley tried out the diet and spoke to O’Mara, the 63-year-old physician — who describes himself as the only one “in the world specializing in Health and Performance Optimization” — suddenly steered the topic to his bowel movements. As one does during casual conversation, he pulled up the Bristol Stool Chart, which categorizes different kinds of poop, and said his was Type 4 (“smooth, soft, like a snake.”)
“When you start eating healthy, you don’t need toilet paper,” he claimed, per the NYT. “Animals in the wild have no residual stool on their anus.”
A proper number two, he explained to Staley, would be odorless, wipe-free, take just a few seconds, and be “nearly orgasmic.”
That’s when Staley boasted about his stealthy rectal ability.
“I could have a bowel movement behind a sheet at a dinner party in the corner of the room and nobody would know,” O’Mara declared.
Whether or not it endows its followers with fantastic defecation powers, doctors are generally pretty skeptical about O’Mara’s diet, which, as a reminder, asks you to only eat beef — preferably steak — and fermented foods like kimchi, sauerkraut, and cheese.
Marion Nestle of New York University told Staley that the diet would be effective for temporary weight loss, because of how lean and satiating the meat is. But one of O’Mara key claims is that the bacteria of fermented foods help repopulate your gut bacteria and drive up your metabolism — something that the science is more iffy on. There’s also the clear cancer risk of consuming so much red meat.
Prediction markets like Kalshi and Polymarket have long garnered a reputation for allowing users to make all kinds of ethically dubious bets, from the outcomes of deadly conflicts to mass famine.
As the New York Times reports, Kalshi will now even allow users to bet on whether clinical trials for potentially lifesaving drugs will succeed.
To critics, the move will effectively allow betting on the lives of patients trying a final intervention in the face of a lethal diagnosis. There’s even risk that those enrolled in these trials could choose to drop out if the market were to bet against a positive outcome.
“Turning loose a betting market in an ongoing randomized clinical trial really is a breach of scientific conduct,” Robert Califf, who served as FDA commissioner in the Biden administration, told the NYT.
Kalshi first announced its “biotech prediction markets pilot program” last month, the same day president Donald Trump’s teleprompter guy was busted for winning more than $100,000 on Kalshi by betting on what he would say.
The company argued in the announcement that a “publicly listed contract on a trial or regulatory outcome produces a continuously updated, public probability that reflects the weight of the evidence rather than the preferred messaging of the trial sponsor.”
In a statement to the NYT, spokesperson Jack Such argued that these bets wouldn’t undermine research integrity, but instead cut through the hype surrounding biotech companies and the drugs they’re working on.
Kalshi says it will prohibit betting by patients enrolled in a trial, as well as by employees of the company conducting it or its competitors, per the NYT. It will also ban betting on trials that “exclusively enroll minors,” at least at first.
But those enrolled in drug trials were left appalled by the news.
“We’re literally trying to stay alive,” metastatic pancreatic cancer patient Walter Ingaharro Jr told the NYT. “It’s not a game. The introduction of gambling into the process really creates an ethical mess.”
In an opinion piece for The Guardian, Boston University humanities professor Joshua Pederson talked about how his 12-year-old son has a “very aggressive tumor growing inches below his heart.”
“If Kalshi has its way, you could soon be able to bet on health treatments that could be essential to his survival,” Pederson argued.
While choosing a trial for his son’s cancer was a “terrifying experiment for which we feel ill-prepared,” turning to a prediction market instead of “our extremely qualified team of oncologists” feels “preposterous,” Pederson argued.
In short, it’s yet another example of prediction markets crossing a moral boundary by gamifying things with real-world consequences.
“The possibility that somebody out there might be wagering against my son, hoping that the treatment fails so they can make money, is enraging,” Pederson wrote. “How is this not just another type of ‘death market’ — like markets for war or assassination — that even Kalshi says it won’t abide?”
The headline of this story was updated to specify that the program would bet on the outcomes of clinical trials, and the piece was updated to more specifically refer to controversies around prediction markets like Kalshi, writ large, and to add details about Kalshi’s response.
Veterinary students at the University of Georgia learned to care for honeybees, which are vital pollinators for U.S. agriculture. Between 2024 and 2025 more than half of the managed colonies in the U.S. have been lost.
In a perspective paper published in The American Journal of Clinical Nutrition, a team of researchers and health experts calls for a ‘paradigm shift’ in how public health agencies address hypertension.
Authorities are struggling to get the outbreak of an explosive diarrhea-causing parasite under control. According to the Centers for Disease Control and Prevention, there are more than 18,000 cases that have been confirmed or are being investigated across 45 states.
There had been 423 reported hospitalizations, but at least no deaths — until this week. On Monday, Michigan health officials confirmed that there are now two fatalities linked to the outbreak, an intestinal illness called cyclosporiasis which is caused by the microscopic parasite Cyclospora cayetanensis.
However, it’s important to note that both individuals had “significant underlying health conditions that may have been impacted by cyclosporiasis and dehydration,” according to an update by Michigan Health and Human Services. In other words, both people didn’t die purely because they were infected by the parasite.
Cyclosporiasis is a gastrointestinal illness that causes watery and frequent diarrhea. There are specific treatments available for the infection, including sulfonamides, which are synthetic antimicrobial agents.
The vast majority of people recover after a few days, weeks, or even a month in severe cases. But in combination with a slew of pre-existing conditions, the illness can prove fatal, as the latest news highlights.
Michigan has been hit particularly hard, representing the majority of cases being tracked, with 11,234 reports and almost 200 hospitalizations. Fortunately, the numbers are starting to wane — though it’s far too early to tell if the state is out of the woods just yet.
“We have growing confidence that the outbreak is declining,” Michigan health department spokeswoman Michigan’s health department told the New York Times.
Despite plenty of evidence to the contrary, White House officials declared the outbreak “under control” on July 21. Cases of the illness have risen more than tenfold since then.
Login
Clearing amyloid plaques may break the chain reaction that fuels brain cell destruction in Alzheimer’s disease. One Alzheimer’s brain offered researchers something they almost never get to see: a natural side-by-side experiment. In some regions, years of anti-amyloid treatment had removed most of the sticky plaques associated with Alzheimer’s disease (AD). Those areas contained little [...]